Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 12.25B 10.5B 9.84B 8.99B 16.96B 1,168B 17.12B 116B 45.17B 589B 46B 45B 1,951B P/E 2026 *
-24.4x
P/E 2027 * -18.6x
Enterprise Value 11.42B 9.78B 9.17B 8.37B 15.81B 1,089B 15.96B 108B 42.1B 549B 42.87B 41.94B 1,819B EV / Sales 2026 *
24.7x
EV / Sales 2027 * 34.1x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
08-24 Arrowhead Pharmaceuticals Presents New Clinical Data and Product Updates At European Society of Cardiology Congress CI
08-20 Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,012,680, According to a Recent SEC Filing MT
08-17 Arrowhead Pharmaceuticals' Redemplo Now Available in Germany for FCS Patients MT
08-17 Arrowhead Pharmaceuticals Lists REDEMPLO In Lauer-Taxe Database As Adjunct To Diet To Reduce Triglyceride Levels In Adult Patients With Familial Chylomicronaemia Syndrome In Germany CI
08-04 Arrowhead Pharmaceuticals, Inc., Q3 2026 Earnings Call, Aug 04, 2026
08-04 Arrowhead Pharmaceuticals Fiscal Q3 Loss Widens, Revenue Rises MT
08-04 Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Fiscal Q3 Loss $1.36, vs. FactSet Est of $1.28 Loss MT
08-04 Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q3 Revenue $75.3M, vs. FactSet Est of $44.2M MT
08-04 Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-30 B. Riley Adjusts Arrowhead Pharmaceuticals Price Target to $123 From $101, Maintains Buy Rating MT
07-29 RBC Raises Price Target on Arrowhead Pharmaceuticals to $100 From $87, Keeps Outperform, Speculative Risk MT
07-27 Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia CI
07-27 Arrowhead Completes Enrollment in Phase 3 Study of Treatment for Homozygous Familial Hypercholesterolemia MT
1 day+2.48%
1 week+1.11%
Current month+5.00%
1 month+3.92%
3 months+12.96%
6 months+44.25%
Current year+33.88%
1 week 85.5
Extreme 85.5
90.21
1 month 81.61
Extreme 81.61
90.97
Current year 54.02
Extreme 54.02
95.49
1 year 20.59
Extreme 20.59
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap.
8/18/26 Sell

Director

-2,000 0.0014%
8/18/26 Sell

Director

-11,600 0.0082%
6/15/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
+2.48%+1.11%+329.16%+218.45% 12.25B
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.74%+2.81%+55.45%+88.75% 63.06B
+1.09%+22.96%+8.55%-3.03% 28.34B
-0.07%-3.56%-3.45%+467.26% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.37%+39.87%-15.08% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+3.98%+6.78%+49.66%+157.94% 13.52B
Average +2.63%+3.32%+89.52%+200.66% 29.36B
Weighted average by Cap. +2.63%+2.73%+71.53%+160.69%

Financials

2026 *2027 *
Net sales 463M 396M 371M 339M 640M 44.1B 647M 4.38B 1.71B 22.25B 1.74B 1.7B 73.68B 339M 291M 273M 249M 470M 32.36B 474M 3.21B 1.25B 16.33B 1.27B 1.25B 54.07B
Net income -504M -432M -405M -370M -698M -48.05B -705M -4.77B -1.86B -24.24B -1.89B -1.85B -80.29B -655M -561M -526M -480M -907M -62.44B -916M -6.2B -2.41B -31.5B -2.46B -2.41B -104B
Net Debt -832M -713M -668M -610M -1.15B -79.35B -1.16B -7.88B -3.07B -40.04B -3.13B -3.06B -133B -683M -585M -548M -501M -945M -65.09B -954M -6.47B -2.52B -32.84B -2.56B -2.51B -109B
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
26-08-25 US$88.88 +2.48% 983,030
26-08-24 US$86.73 -0.44% 1,104,529
26-08-21 US$87.11 -0.41% 1,090,199
26-08-20 US$87.47 -2.17% 896,882
26-08-19 US$89.41 +1.72% 1,363,714
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
86.73USD
Average target price
110.18USD
Spread / Average Target
+27.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARWR Stock